Saturday May 27th 2017

Dimethyl fumarate (BG-12, Tecfidera) – NICE gives initial "no" decision

The MS Trust is disappointed that NICE does not intend to recommend that dimethyl fumarate (Tecfidera) be made available as a treatment on the NHS in England and Wales. (Source: Multiple Sclerosis Trust)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read More: 

Dimethyl fumarate (BG-12, Tecfidera) – NICE gives initial "no" decision

Leave a Comment

More from category

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]

Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS
Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS

Gadolinium accumulation in the brain is greater with linear GBCAs than with macrocyclics. Multiple sclerosis experts [Read More]